PT1173434E - Novo produto farmaceutico - Google Patents

Novo produto farmaceutico

Info

Publication number
PT1173434E
PT1173434E PT00920889T PT00920889T PT1173434E PT 1173434 E PT1173434 E PT 1173434E PT 00920889 T PT00920889 T PT 00920889T PT 00920889 T PT00920889 T PT 00920889T PT 1173434 E PT1173434 E PT 1173434E
Authority
PT
Portugal
Prior art keywords
pharmaceutical product
new pharmaceutical
new
product
pharmaceutical
Prior art date
Application number
PT00920889T
Other languages
English (en)
Inventor
Robert Gordon Giles
Paul David James Blackler
Michael John Sasse
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1173434(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9909472.4A external-priority patent/GB9909472D0/en
Priority claimed from GBGB9912197.2A external-priority patent/GB9912197D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PT1173434E publication Critical patent/PT1173434E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
PT00920889T 1999-04-23 2000-04-19 Novo produto farmaceutico PT1173434E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9909472.4A GB9909472D0 (en) 1999-04-23 1999-04-23 Novel compounds
GBGB9912197.2A GB9912197D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
PT1173434E true PT1173434E (pt) 2003-12-31

Family

ID=26315460

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02080320T PT1284268E (pt) 1999-04-23 2000-04-19 Preparação de uma forma polimórfica de um derivado de tiazolidinodiona
PT00920889T PT1173434E (pt) 1999-04-23 2000-04-19 Novo produto farmaceutico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT02080320T PT1284268E (pt) 1999-04-23 2000-04-19 Preparação de uma forma polimórfica de um derivado de tiazolidinodiona

Country Status (40)

Country Link
US (2) US6815457B1 (pt)
EP (3) EP1173434B1 (pt)
JP (1) JP2002543075A (pt)
KR (1) KR100744359B1 (pt)
CN (1) CN1208335C (pt)
AP (1) AP1495A (pt)
AR (2) AR023564A1 (pt)
AT (2) ATE247653T1 (pt)
AU (1) AU765498B2 (pt)
BG (1) BG65427B1 (pt)
BR (1) BR0009934A (pt)
CA (1) CA2370258A1 (pt)
CO (1) CO5170424A1 (pt)
CY (1) CY1107238T1 (pt)
CZ (1) CZ20013799A3 (pt)
DE (2) DE60004658T2 (pt)
DK (2) DK1284268T3 (pt)
DZ (1) DZ3155A1 (pt)
EA (1) EA004534B1 (pt)
ES (2) ES2298327T3 (pt)
HK (2) HK1055293A1 (pt)
HR (1) HRP20010773B1 (pt)
HU (1) HUP0200929A3 (pt)
IL (1) IL146110A0 (pt)
MA (1) MA26785A1 (pt)
MX (1) MXPA01010820A (pt)
MY (1) MY128007A (pt)
NO (1) NO320589B1 (pt)
NZ (1) NZ515163A (pt)
OA (1) OA11871A (pt)
PE (1) PE20010040A1 (pt)
PL (1) PL351686A1 (pt)
PT (2) PT1284268E (pt)
RS (1) RS50114B (pt)
SK (1) SK286423B6 (pt)
TR (1) TR200103061T2 (pt)
TW (1) TW591027B (pt)
UA (1) UA67843C2 (pt)
UY (1) UY26120A1 (pt)
WO (1) WO2000064892A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
AP1598A (en) * 1999-04-23 2006-04-26 Smithkline Beecham Plc Polymorph of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt.
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
EP1173434B1 (en) 1999-04-23 2003-08-20 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
WO2002026737A1 (en) * 2000-09-26 2002-04-04 Dr. Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
US7241895B2 (en) * 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
AU2002352391A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
EP0306228B1 (en) 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US20010044458A1 (en) * 1994-02-10 2001-11-22 Smithkline Beechamp P.L.C. Use of insulin sensitisers for treating renal diseases
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
WO1995021608A1 (en) 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
GB9711683D0 (en) 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
PL337577A1 (en) 1997-06-18 2000-08-28 Smithkline Beecham Plc Treatment of diabetes with thiazolydinone and alpha - glucosidaze inhibitor
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
ATE355840T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
CN1168451C (zh) 1997-06-18 2004-09-29 史密丝克莱恩比彻姆有限公司 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
US20020045649A1 (en) * 1997-07-18 2002-04-18 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
AP1598A (en) 1999-04-23 2006-04-26 Smithkline Beecham Plc Polymorph of 5-[4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt.
WO2000064893A2 (en) 1999-04-23 2000-11-02 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
EP1173434B1 (en) 1999-04-23 2003-08-20 SmithKline Beecham plc Thiazolidinedione derivative and its use as antidiabetic
WO2002026737A1 (en) 2000-09-26 2002-04-04 Dr. Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation

Also Published As

Publication number Publication date
UA67843C2 (uk) 2004-07-15
WO2000064892A3 (en) 2001-01-25
SK14912001A3 (sk) 2002-02-05
IL146110A0 (en) 2002-07-25
MXPA01010820A (es) 2002-06-04
CA2370258A1 (en) 2000-11-02
EP1903043A1 (en) 2008-03-26
NZ515163A (en) 2004-02-27
MA26785A1 (fr) 2004-12-20
EP1284268A1 (en) 2003-02-19
RS50114B (sr) 2009-03-25
HK1045154B (zh) 2004-06-25
EA004534B1 (ru) 2004-06-24
WO2000064892A2 (en) 2000-11-02
EP1173434A2 (en) 2002-01-23
TW591027B (en) 2004-06-11
US6815457B1 (en) 2004-11-09
DK1173434T3 (da) 2003-12-08
HK1055293A1 (en) 2004-01-02
OA11871A (en) 2006-03-27
JP2002543075A (ja) 2002-12-17
AU765498B2 (en) 2003-09-18
AP1495A (en) 2005-11-30
NO320589B1 (no) 2005-12-27
HRP20010773B1 (en) 2005-06-30
HRP20010773A2 (en) 2002-10-31
CN1208335C (zh) 2005-06-29
EP1173434B1 (en) 2003-08-20
CO5170424A1 (es) 2002-06-27
ES2204557T3 (es) 2004-05-01
KR100744359B1 (ko) 2007-07-30
YU75201A (sh) 2004-09-03
CZ20013799A3 (cs) 2002-04-17
DE60037602D1 (de) 2008-02-07
DE60004658D1 (de) 2003-09-25
NO20015149D0 (no) 2001-10-22
MY128007A (en) 2007-01-31
US20040092555A1 (en) 2004-05-13
DE60004658T2 (de) 2004-06-24
SK286423B6 (sk) 2008-09-05
BR0009934A (pt) 2002-06-04
AU4130600A (en) 2000-11-10
CY1107238T1 (el) 2012-11-21
BG106119A (en) 2002-05-31
PT1284268E (pt) 2008-03-10
CN1355801A (zh) 2002-06-26
DZ3155A1 (fr) 2000-11-02
HK1045154A1 (en) 2002-11-15
DK1284268T3 (da) 2008-04-28
UY26120A1 (es) 2000-12-29
HUP0200929A3 (en) 2004-03-29
NO20015149L (no) 2001-12-17
EP1284268B1 (en) 2007-12-26
ATE247653T1 (de) 2003-09-15
EA200101119A1 (ru) 2002-04-25
PE20010040A1 (es) 2001-03-10
HUP0200929A2 (en) 2002-08-28
DE60037602T2 (de) 2009-01-08
PL351686A1 (en) 2003-06-02
ATE382046T1 (de) 2008-01-15
KR20020028873A (ko) 2002-04-17
TR200103061T2 (tr) 2002-05-21
AR023564A1 (es) 2002-09-04
BG65427B1 (bg) 2008-07-31
AR023568A1 (es) 2002-09-04
ES2298327T3 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
PT1173434E (pt) Novo produto farmaceutico
NO20022970L (no) Hydrogel-drevet medikamentdoseringsform
NO20015175L (no) Farmasöytisk sammensetning
DE60040876D1 (de) Medikamentenzuführeinrichtung
ATE352339T1 (de) Medikamentspender
PT1242087E (pt) Composicoes farmaceuticas
NO20020086D0 (no) Smaksmaskerte farmasöytiske flytende formuleringer
DK1200092T3 (da) Beta-carbolin-lægemiddelprodukter
NO20015670L (no) Forbedrede farmasöytiske formuleringer
NO20022606L (no) Farmasöytiske kombinasjoner
DK1275397T3 (da) Lægemiddel til lokal anvendelse
NO20014926D0 (no) Farmasöytiske forbindelser
PT1239832E (pt) Composicoes farmaceuticas
EG23937A (en) Novel pharmaceutical
ITMI20001827A0 (it) Medicamento antinfiammatorio
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
PL351135A1 (en) Novel pharmaceutical
NO20016430D0 (no) Farmasöytisk kompleks
EG23946A (en) Novel pharmaceutical
NO991359D0 (no) Tablettdispenser
GB9923933D0 (en) Novel pharmaceutical
ATA173599A (de) Pharmazeutisches produkt
GB9923934D0 (en) Novel pharmaceutical
UA2855S (uk) Таблетка фармацевтична